The combined sales of seven new therapies to treat breast cancer will total nearly $5bn in Europe and Japan by 2019, according to a report by Decision Resources.
Surveyed experts were particularly enthusiastic about agents in the Poly ADP-Ribose Polymerase (PARP) inhibitor drug class.
A Pharmacor 2010 breast cancer report revealed that Sanofi-Aventis' PARP inhibitor iniparib has the potential to achieve blockbuster peak-year sales in excess of $1bn.
Other key drugs in development include AstraZeneca's olaparib and Abbott Laboratories' veliparib.
Sales of agents targeting HER2-positive breast cancer will increase by almost $2bn billion through to 2019, fuelled by increased uptake of Roche / Chugai's Herceptin, GlaxoSmithKline's Tykerb / Tyverb and the approval of Roche / Genentech / Chugai's trastuzumab-DM1, Roche / Chugai's Omnitarg and Pfizer's neratinib.